Careers

Diversity

With 18 offices, from New York to Los Angeles and Seattle to Orlando, we live and work in communities all over the U.S., collaborating across locations, disciplines and even borders. Our experienced, highly ranked lawyers serve businesses wherever they are and wherever they want to go.

Offices

About Us

Pages

Professionals

Thought leadership: blogs, podcasts, videos, publications, events and news

Insights

Practices & Industries

Pro Bono

Am Law 100 firm with practices in Business, Digital Assets and Data Management, Intellectual Property, Labor & Employment, Litigation and Tax.

Home | BakerHostetler

Stefanie Ferrari Speaks at 4th Annual SecureWorld Healthcare Virtual Conference

Blockchain Monitor

Blockchain Monitor - Planet earth in outer space with network connection and sunlight.

Weekly Blockchain Blog – Feburary 17, 2026

Randal Shaheen Joins Panel for PLI’s Advertising Law Institute 2026

Data Counsel

“The Times They Are A-Changin’”: GSA Signals a New Era for CUI Compliance

The Supreme Court seemed, at least to a small degree, interested in evaluating the subject matter eligibility of diagnostic claims when it requested that the respondents (Natera Inc. and Eurofins Viracor Inc.) respond to a petition for writ of certiorari filed by CareDx Inc. and the Board of Trustees of the Leland Stanford Junior University (collectively “CareDx”). CareDx had asked the Court to address the following <a href="/blogs/will-the-supreme-court-reevaluate-the-subject-matter-eligibility-of-diagnostic-claims/">question</a>:

core/paragraph


<p style="padding-left: 40px;">Congress has provided that any “new and useful process” is eligible for patent protection, and that “any new and useful improvement thereof” is also eligible for patent protection. 35 U.S.C. 101. The question presented is whether a new and useful method for measuring a natural phenomenon, that improves upon prior methods for measuring that very same phenomenon, is eligible for patent protection under Section 101.</p>

core/freeform

But the Court denied CareDx’s petition, continuing its trend of refusing to reevaluate subject matter eligibility in the life sciences space and beyond. From the Order List issued by the Court on Oct. 2, we at least know that Justice Brett Kavanaugh would have granted the petition. Once again, we wait for another case to be brought to the Court or for Congress to act.

The Supreme Court Again Declines To Reevaluate Subject Matter Eligibility of Diagnostic Claims

Featured Insights

Related Services

Featured Insights